1. Interactive Effects of HDAC Inhibitors and TRAIL on Apoptosis Are Associated with Changes in Mitochondrial Functions and Expressions of Cell Cycle Regulatory Genes in Multiple Myeloma
   Tamer E. Fandy et al, 2005, Neoplasia CrossRef
2. Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance
   Alessandra Zingoni et al, 2017, Front. Immunol. CrossRef
3. p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death
   Maria Mrakovcic et al, 2019, IJMS CrossRef
4. Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics.
   Rehmat Jan et al, 2019, Adv Pharm Bull CrossRef
5. Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy.
   Mohammed I Y Elmallah et al, 2019, Cancers (Basel) CrossRef
6. Epigenetic Metalloenzymes
   Christophe Blanquart et al, 2019, CMC CrossRef
7. Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors
   Pierre Autin et al, 2019, Cancers CrossRef
8. Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy
   Nilanjan Adhikari et al, 2021, J. Med. Chem. CrossRef
9. Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms
   Sharmila Shankar et al, 2008 CrossRef
10. Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275
    Ilker Y. Eyüpoglu et al, 2006 CrossRef
11. Sulforaphane Enhances the Therapeutic Potential of TRAIL in Prostate Cancer Orthotopic Model through Regulation of Apoptosis, Metastasis, and Angiogenesis
    Sharmila Shankar et al, 2008 CrossRef
12. Histone Deacetylase Inhibitors Enhance Lexatumumab-Induced Apoptosis via a p21Cip1-Dependent Decrease in Survivin Levels
    Steffan T. Nawrocki et al, 2007 CrossRef